PeptideClinicLocatorOverview
PE-22-28 is a synthetic peptide derived from spadin, studied in preclinical and animal studies for antidepressant effects and cognitive enhancement. It is not FDA-approved and is research only. There are no human clinical trials establishing safety or efficacy. It would be administered by subcutaneous injection or intranasally in research settings. Patients should not use PE-22-28 outside of approved research; evidence is emerging and preclinical/animal only. For depression or cognitive concerns, evidence-based, FDA-approved treatments and legal supplements are the appropriate path.
How It Works (Mechanism of Action)
Spadin-derived peptides are thought to modulate ion channels and neurotransmitter systems involved in mood and cognition. Mechanisms are under investigation in preclinical work.
Primary Uses
Antidepressant effects, cognitive enhancement (research only). Not FDA-approved. Preclinical/animal studies only.
FDA & Regulatory Status
Not FDA-approved. Research only.
Last reviewed February 2026.
Clinical Evidence
Emerging—preclinical/animal studies. No human trials.
Side Effects & Safety
Unknown in humans. Not for human use outside research.
